Resmetirom is an oral, liver-targeting, once-daily THRβ-selective agonist, which in December 2022 became the first drug to meet its primary endpoints in Ph. III for NASH, demonstrating both NASH resolution and no worsening of fibrosis by biopsy over placebo in 316 test patients. Madrigal will file an NDA for resmetirom in 2023, allowing it to [...]
< 1 minute read
Mar. 13, 2023
Resmetirom: an Oral, Liver-Targeting, Once-Daily THRβ-Selective Agonist
Madrigal THRβ-selective agonist
oral, QD THRβ-selective agonist Ph. III for NASH opt. of triiodothyronine resmetirom (MGL-3196) Madrigal Pharmaceuticals, West Conshohocken, PA
Loading...
